Related Experiment Videos
Management of hypertension, Part II
1Yale University School of Medicine, New Haven, Connecticut, USA.
Insights
Calcium channel blockers and ACE inhibitors effectively lower blood pressure, but long-term effects on patient outcomes require further study. ACE inhibitors show benefits for heart failure and diabetic hypertension, but not stroke prevention.
Area of Science:
- Cardiology
- Pharmacology
- Nephrology
Background:
- Calcium channel blockers (CCBs) and angiotensin-converting enzyme (ACE) inhibitors are common antihypertensives.
- Long-term data on their impact on morbidity and mortality in hypertension are limited.
- Current guidelines suggest them as initial therapy options.
Purpose of the Study:
- To review the current evidence on the effects of CCBs and ACE inhibitors on morbidity and mortality in hypertensive patients.
- To highlight specific benefits and limitations of these drug classes in various patient populations.
Main Methods:
- Review of existing clinical trial data and epidemiological studies.
- Analysis of drug efficacy in reducing cardiovascular events and mortality.
- Focus on specific patient subgroups, including those with ischemic heart disease, diabetes, and heart failure.
Main Results:
- Short-acting CCBs should be used cautiously in hypertension. Nonhydropyridine CCBs may reduce reinfarction but not mortality in ischemic heart disease.
- ACE inhibitors improve insulin sensitivity and reduce intraglomerular pressure, making them preferred for hypertensive diabetics, especially with nephropathy.
- ACE inhibitors reduce heart failure morbidity and mortality in patients with poor left ventricular function, but do not prevent strokes or heart attacks in hypertensive patients.
Conclusions:
- ACE inhibitors offer significant benefits for specific patient groups, particularly heart failure and diabetic nephropathy.
- Further long-term studies are needed to fully elucidate the morbidity and mortality benefits of both drug classes in hypertension.
- Careful patient selection and consideration of drug-specific profiles are crucial for optimal hypertension management.
Abstract:
Although calcium channel blockers and angiotensin-converting enzyme (ACE) inhibitors are effective in lowering blood pressure, no long-term data show their effect on morbidity and mortality in hypertensive patients. They are suggested as alternative initial therapy in hypertensive patients. Short-acting calcium channel blockers are to be used with caution or not at all in the treatment of hypertension. Nonhydropyridine calcium channel blockers may reduce the incidence of second infarction but not congestive heart failure or mortality in patients with ischemic heart disease. The ACE inhibitors increase insulin sensitivity and decrease intraglomerular pressure. In combination with a diuretic, they are the preferred agents in the treatment of diabetic patients with hypertension, especially those with nephropathy. In both hypertensive and normotensive patients, ACE inhibitors reduce morbidity and mortality resulting from congestive heart failure in patients with poor left ventricular function who are also being treated with a diuretic and/or digitalis. They do not, however, reduce strokes or myocardial infarctions in hypertensive patients.